According to our recent payer coverage analysis for PCSK9 inhibitors, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access for PCSK9 inhibitors shows that more than 90% of the lives under the pharmacy benefit in commercial and health exchange formularies have utilization management restrictions.
Trends: In October 2018, Amgen said that it would reduce the price of its Repatha SureClick autoinjector to $5,850 per year.
To read the full Reality Check on PCSK9 inhibitors with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: